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DANSK RESUMÉ (DANISH SUMMARY) 
Blodforgiftning med gul Stafylokok (SAB) er en livstruende infektion, som rammer både børn og 
voksne over hele verden. En frygtet komplikation til blodforgiftningen er hjerteklapsbetændelse, hvoraf 
30–40% af patienterne dør inden for et år. Flere risikofaktorer for SAB er identificeret blandt voksne, 
men der er fortsat uafklarede spørgsmål. Identifikation af faktorer som øger risikoen for SAB har stor 
betydning for muligheden for forebyggelse og tidlig opsporing af denne alvorlige sygdom. Hos voksne 
er det usikkert om socioøkonomisk status øger forekomsten af sygdommen, hvis alle har lige adgang 
til sundhedsvæsnet og det er uklart om social status påvirker risikoen for efterfølgende at få 
betændelse på hjerteklapperne hos patienter med SAB. Hos børn er viden om risikofaktorer for SAB 
mangelfuld, og eksisterende studier er præget af begrænsninger i forhold til design og få patienter. 
Det er ligeledes aldrig undersøgt om blodforgiftningen ophobes i familier. En familiær ophobning vil 
tyde på, en genetisk disposition til en øget modtageligheden over for bakterien gul Stafylokok.   
Ved at sammenkoble landsdækkende registre via hver persons CPR-nummer indhentede vi 
oplysninger om bl.a. uddannelse,  sygdomme, medicin,  operationer, familierelationer og 
mikrobiologisk verificeret SAB for hvert individ.  
Hovedresultaterne var: Artikel I) Hos voksne var lav socioøkonomisk status associeret med en 
øget forekomst af SAB, men sammenhængen blev svagere med stigende alder. Der var ingen 
association mellem socioøkonomisk status, og udvikling af hjerteklapsbetændelse hos patienter med 
SAB. Artikel II) Hos børn (5–18 år) var forekomsten af SAB højest blandt børn som modtog dialyse 
eller plasmaferese, var transplanteret, havde kræft, børneeksem, medfødt hjertesygdom eller var 
nyopererede, men mere end hver tredje barn med sygdommen var tidligere rask. For tidlig fødsel og 
forældrenes socioøkonomiske status påvirkede ikke forekomsten af blodforgiftningen. Artikel III) 
Raten af SAB var dobbelt så høj i familier, hvor en førstegradsslægtning havde haft sygdommen 
sammenlignet med baggrundsraten. Den højeste rate fandt vi, når ens søskende havde været syg og 
havde erhvervet infektionen uden for hospitalet. Smitte og miljøfaktorer var formentlig ikke 
forklaringen, da >80% af familierne var inficeret med genetisk forskellige gule Stafylokokker, og vi 
ikke observerede en  øget forekomst af SAB fandt blandt ægtefolk. 
Identifikation af risikofaktorer for SAB hos både voksne og børn (Artikel I og II) kan være med til at 
øge sundhedsfagliges opmærksomhed over for sygdommen og derved både bedre diagnosticering, 
sikre igangsættelse af tidlig behandling samt forbedre forebyggelse af SAB. Ligeledes kan viden om 
familiær ophobning (Artikel III) bane vejen for fremtidige genetiske studier for at øge forståelsen for 
sygdommen, samt potentielt identificere særlige risikogrupper, hvor sundhedsfaglige bør være særligt 
opmærksomme på sygdommen og eventuelt forebyggende tiltag.  
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ENGLISH SUMMARY 
Staphylococcus aureus bacteremia (SAB) is of great concern worldwide due to the frequently fatal 
outcome, or endocarditis as a dreaded complication with a one-year mortality rate of 30–40%. 
Multiple factors increasing the risk of SAB have been identified, but whether socioeconomic status is 
associated with the adult risk of SAB in a society with a universal healthcare system or whether social 
status is associated with subsequent endocarditis in SAB patients is not fully elucidated. Further, 
knowledge on risk factors in the pediatric population is sparse and the current literature is limited by 
small numbers of patients and study design. Additionally, to the best of our knowledge a possible 
familial clustering of SAB has never been investigated. To improve future diagnosis, treatment and 
prognosis for patients with SAB, identification of exposures associated with increased rate of the 
disease, are essential to ensure early diagnosis. Moreover, a familial clustering of SAB would point 
towards a possible genetic component in the human susceptibility to S. aureus.   
We cross-linked national registries at an individual level by use of each individual’s personal 
identification number to obtain information on demographics, education, comorbidities, medication, 
surgical procedures, family relations, and microbiologically verified SAB.  
The main results of this thesis were: Paper I) In adults, a low socioeconomic status was 
associated with an increased risk of SAB, and this association declined with advancing age. The level 
of socioeconomic status did not influence the risk of subsequent infective endocarditis in patients with 
bacteremia. Paper II) In children aged 5–18 years, the highest rates of SAB were observed in children 
receiving dialysis or plasmapheresis, transplanted children, children with cancer, congenital heart 
disease, atopic dermatitis and in children with recent surgery. However, more than every third child 
with bacteremia were presumably healthy prior to the hospital admission for SAB. Neither parental 
socioeconomic status nor prematurity were associated with the risk of SAB in these children. Paper 
III) Having a first-degree relative previously hospitalized with SAB was associated with a more than 
two-fold increased rate of the disease compared with the background population. The highest risk of 
acquiring the bacteremia was observed if a first-degree relative was a sibling with non-hospital 
acquired SAB. Contagion could probably not explain our findings, since the causative S. aureus strain 
differed genetically in more than 80% of the infected families, and no increased risk was observed in 
spouses.  
Knowledge on risk factors for SAB in both adults and children (Paper I and Paper II) may increase 
the awareness of the disease, thus improving early diagnosis and correct treatment. Lastly, 
knowledge on familial clustering of the disease can pave the way for future clinical genetic studies 
leading to prevention of familiar clustering.  
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BACKGROUND 
Staphylococcus aureus bacteremia (SAB) strikes people of all ages and may result in severe 
morbidity and mortality even in young and healthy individuals. The risk of SAB is influenced by 
multiple factors, and the interplay between host and microorganism is complex and far from 
elucidated. To prevent SAB and improve patient prognosis it is essential to understand to what extend 
non-genetic host factors are associated with an increased infection risk in both adults and children. 
Since genetic variation has also been implicated in increased susceptibility to Staphylococcus aureus 
(S. aureus) in animals and in a few human studies, it is also of great interest to investigate if the 
disease clusters in families as an indication of a possible genetic component in the human 
susceptibility to this pathogen.     
 
Staphylococcus aureus (S. aureus) 
S. aureus is a gram-positive bacterium which was first identified in 1880 in a knee joint and have ever 
since been a challenge to the healthcare system worldwide (1). The bacterium is a colonizing 
opportunistic pathogen residing on the human body and is a pathogen to man and other mammals. 
Approximately 20–25% of the Danish population are colonized S. aureus persistently in their nasal 
flora, and up till 50% are transient carriers (2,3). Besides bacteremia, S. aureus may cause a variety 
of diseases in humans ranging from superficial infections of the skin (e.g. impetigo and furuncles) to 
potential life-threatening diseases such as toxic shock syndrome, meningitis, endocarditis and 
osteomyelitis (4). To enter the host, S. aureus utilizes surface and virulence factors to damage the 
host tissue, block the innate immune response pathways and counteract the phagocytic engulfment 
(4). The pathogen is also known for its ability to colonize foreign bodies (e.g. pacemaker leads and 
joint prosthesis) with biofilm, thus infecting implanted body material while impeding the response from 
the immune system of the host (5). Further, in recent decades S. aureus has evolved to become 
multi-resistant to a large number of antimicrobial agents (6). In Denmark approximately 71–78% of all 
S. aureus strains are resistant to penicillin (7), whereas methicillin resistant S. aureus (MRSA) 
comprises only approximately 2% of the strains cultured in SAB patients, making the frequency of 
MRSA among SAB isolates very low compared with other countries such as the US where up to 60% 
of S. aureus infections in US intensive care units are caused by MRSA (8). Further, in Denmark an 
increased rate of MRSA (both carriers and infected people) has been observed in the community 
since 2000, Figure 1.  
 
Figure 1: The incidence of new MRSA cases (carriers and infected individuals) in 
Denmark from 1990–2016 
  
The figure is from the annual report on SAB with permission from the National Surveillance Department. 
Each patient only included one time unless found positive with a new strain type The increase in MRSA 
in 2014 might be explained by an increased screening for MRSA in pigs. 
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Staphylococcus aureus bacteremia (SAB)  
Although intermediately fluctuating, in Denmark the incidence rate of SAB has increased 
continually over the past decades. In 2016 the annual incidence of SAB exceeded 34,7/100,000 
inhabitants, Figure 2.  
 
Figure 2: Incidence rate of SAB per 100,000 inhabitants from 1990–2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bloodstream infection can be categorized according to the presumed acquisition (hospital 
acquired [HA], health-care related [HCR] and community acquired [CA]) and can occur as non-
complicated or be complicated by e.g. endocarditis, orthopedic infections or meningitis (4,5,9–11), 
which prolong hospitalization and increase morbidity and mortality considerably (12–14). 
Nevertheless, the mortality rate in SAB patients has decreased gradually over the last couple of 
decades in Denmark (15,16).  
 
Considering a Danish population with an increasing life expectancy, and a healthcare system, 
which continuously perform more invasive procedures, also in older patients, it is likely that the rate of 
SAB will continue to increase in the future. This only emphasizes the need for identification of risk 
factors to minimize doctor’s delay and ensure an early diagnosis, and thus a better prognosis. 
 
Host factors increasing the risk of SAB  
The incidence rates of SAB have two age peaks, i.e. in the youngest (<1 year of age) and in older 
people (>75 years) (17–20). In children the occurrence of SAB is particularly high within the first year 
of life with a markedly higher rate among neonates (21,22), with premature birth and congenital heart 
disease as important contributing risk factors (22–25). During teenage years the rate of SAB declines 
markedly, remains low during adulthood and increase again with advancing age (2,3). 
Although the reason remains unclear, studies consistently report male sex as an important risk 
factor for SAB. Among Danish patients with SAB, approximately two-thirds are males; a ratio that has 
been relatively constant over the last twenty years (16) and corresponds to what is observed 
elsewhere in the literature in both the adult and pediatric population (22,26).  
Low level of socioeconomic status (SES) has been observed to increase the associated risk of 
SAB in adults in minor studies from Australia, Denmark and New Zealand (19,27,28). The 
associations are mainly explained by a higher prevalence of complicating life-style related 
comorbidities such as diabetes and cardiovascular diseases, as well as a larger occurrence of 
intravenous drug users. In countries without a universal health care system, disparity in the access to 
and quality of medical assistance increases the inequalities in acquisition and outcome of the 
The figure is from the annual report on SAB with permission from the National Surveillance Department  
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bacteremia. Despite the universal health care system in Denmark, also the Danish case-control study 
observed a low SES to be associated with an increased risk of community-acquired bacteremia in 
working-age citizens (27). Further, analyses stratified by pathogen revealed an inverse relationship 
between SES and SAB, but it is not fully elucidated if this relationship persists on a nationwide level 
including all SAB patients (27). It also remains to be shown if the level of SES in SAB patients is 
associated with subsequent infective endocarditis. In relation hereto, it has not been explored if 
parental SES is associated with the risk of SAB in children. A Danish study including children aged 0–
5 years observed that children of parents on early retirement or of parents on sick leave were more 
likely to be hospitalized with an infectious disease compared with children of employed parents (29). 
Additionally, the researchers observed an inverse relationship between parental educational level and 
risk of offspring hospitalization. The association between SES and admission to hospital was 
strongest for ear infections, infection in the lower respiratory tract and gastrointestinal infections. 
Another Danish study examined the impact of socioeconomic factors on the risk of hospital admission 
due to an infectious disease within the first two years of life in children born in the Northern part of 
Jutland (30). Shorter or no maternal education, single mum status and low household income were 
associated with increased risk of hospitalization, but the association with low household income did 
not persist in adjusted models.  
 
Several comorbidities have been observed to be associated with an increased risk of SAB, but 
only very few population-based studies include children and the majority hereof focuses on infants. 
Some shared common risk factors have been identified. Cancer is highly represented among both 
children and adults with SAB. Treatment with chemotherapy, surgery and long hospitalizations have a 
great impact on the infection risk (31–35). Further, a high occurrence of SAB is observed in patients 
with renal diseases especially when renal replacement therapy is required with the highest risk 
observed in patients undergoing hemodialysis (36–38). This has been confirmed in the pediatric 
population (39,40) and the high infection risk is partly due to repetetive intravenous access, central 
venous catheters and a suppressed immune system.  
Other medical conditions prone to increase the disease risk are rheumatoid arthritis, which 
constitutes a significant risk factor for SAB in adults (41,42), and juvenile idiopathic arthritis in children 
(43,44). The inflammatory aspect of the diseases erodes the joints and in conjunction with 
immunosuppressive medication the body defense is impaired, rendering these patients more 
vulnerable to the pathogen. Studies on the relationship between SAB and inflammatory bowel disease 
are few in both the adult and pediatric population, and results are conflicting. But overall data suggest 
an increased rate of SAB. Immune suppressive and immune modulating medicine appear to play an 
important role (45–47). 
Further, adults with diabetes have a substantially increased risk of the infection compared with 
non-diabetic individuals with poor glycemic control, duration of diabetes and complications to diabetes 
as major risk factors (48–52). These associations have, however, not been fully explored in children 
and studies show diverging results (53,54), as is the case for severe liver dysfunction, which in adults 
is associated with increased risk of the infection and a poor prognosis (51,55,56). Other risk factors 
for SAB are HIV (57–60) and injection drug-use (61–63), which are both rare in Danish children but is 
highly associated with SAB in the adult population. 
Any invasive procedure and implantation of a foreign body is a risk factor of infections including 
SAB. The infection risk and type has been observed to differ according to type of implanted device 
(64,65). Moreover, patients receiving organ transplantation has an increased risk of SAB due to the 
invasive procedure, life-long treatment with immunosuppressive medication and the foreign material 
including scar tissue, (66,67).  
Finally, nasal carriage has been shown to increase the risk of SAB (68,69). A number of studies 
have observed a higher risk of the disease among adult carriers compared with non-carriers and also 
that isolates obtained from blood cultures are clonally identical with isolates cultured from the nares in 
a large fraction of SAB patients (69–71). In newborns a study found maternal carrier status and 
antibiotics given during birth to be the most significant predisposing factors to neonatal S. aureus 
carriage (72). A study from Taiwan reported that 10,2% of otherwise healthy children carried MRSA 
with the highest carriage rate observed among infants (73).  
 
 
Genes influencing the susceptibility to S. aureus 
Although the section above describes multiple risk factors for SAB in both adults and children, it is 
not rare that a previously presumed healthy young adult or a child acquire SAB (10,25,74–76), raising 
the question if and to what extend host genetics contributes to the susceptibility to S. aureus.  
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Animal studies have shown that the susceptibility to S. aureus infection differs between different 
inbred mouse strains suggesting that genetic differences could also influence the susceptibility to S. 
aureus infection in humans. More specifically, it has been verified that certain types of inbreeded mice 
are more easily infected by S. aureus compared to other mice (77,78). Specific genetic changes on 
chromosome 7, 8, 11 and 18 have been shown to increase the susceptibility to S. aureus and further 
lead to an insufficient clearance of the infection by the immune system (79,80). Additionally, mice with 
a genetic deficiency resulting in impaired production of complement C5 had an increased 
susceptibility and increased mortality compared with healthy mice without C5 deficiency, when 
exposed to S. aureus (81,82).  
In humans, the prevalence of SAB varies among genetically diverse ethnic populations (18,83–
86). Studies have observed a doubling in incidence of SAB in the African-American population (66.5 
per 100,000 person-years) compared with the Caucasian population (27.7 per 100,000 person-years) 
in the United States and an up to 20-fold increased risk in the Australian indigenous population 
(Aboriginals) compared with nonindigenous Australians (19,87,88). Likewise, in New Zealand the 
occurrence of SAB is more frequent among Pacific Island people and Maori compared with citizens of 
European ethnicity (85,89,90). Although SES influences the risk of SAB as outlined above, this cannot 
fully explain the inequality of S. aureus rates in these ethnic subpopulation (28) and, together with the 
aforementioned findings from animal studies, this suggests that host genetics may influence the 
susceptibility to S. aureus infection in these individuals, but this has yet to be demonstrated. It is well 
known that there is a significant heterogeneity in the health status of patients admitted with SAB, 
ranging from several comorbidities to none. Variation in host genetics could be a pathogenic factor in 
SAB patients. An increased sensitivity to S. aureus infections has been demonstrated in individuals 
suffering from rare genetic disorders, e.g. chronic granulomatous disease (91), IRAK-4 deficiency 
(92), Chediak-Higashis syndrome (93), hyper-IgE syndrome (94) and MyDD8 deficiency (95). A 
genome-wide association study explored whether common variants were associated with increased 
susceptibility to S. aureus but has failed to show convincing results (96).  
If the susceptibility to S. aureus is partly driven by host genetics, it is reasonable to assume that 
SAB clusters in families, but this has not been explored previously. 
Overall, a better understanding of human host genetic factors in relation to susceptibility to S. 
aureus infection is highly warranted.  
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OBJECTIVES AND HYPOTHESES 
The overall purpose of this thesis was to identify human host factors associated with risk of SAB.  
 
Paper I 
The aim of this study was first to investigate whether the level of socioeconomic status (SES) was 
associated with the risk of a first episode of SAB in a nationwide setting, and secondarily if there was 
an association between SES and subsequent risk of infective endocarditis (IE) in patients with SAB. 
We hypothesized that low SES would be associated with both an increased risk of the disease as well 
as increased risk of subsequent IE in patients with SAB.  
 
Paper II 
The aim of this study was to utilize nationwide register data to investigate if predefined risk factors 
were associated with SAB in children aged 5–18 years i.e. in children with a mature immune system, 
and to identify presumably healthy children among children who developed SAB. We hypothesized 
that the absolute incidence rate of SAB in this pediatric population would be significantly lower than in 
studies following children from birth. We theorized that the majority of medical conditions and invasive 
procedures prone to increase the risk of SAB in the adult population would also be associated with 
increased risk of bacteremia in children, and that prematurity, parental SES and congenital disease 
would play an additional role. Lastly, we hypothesized that although the majority of children 
hospitalized with SAB would have a high comorbidity burden prior to the infection a significant 
proportion of the children would have a clean medical record.  
 
Paper III 
The aim of this study was to investigate whether a family history of SAB was associated with 
increased risk of the disease in first-degree relatives, and how potential associations differed 
according to family status (sibling, parent) and mode of acquisition. We hypothesized that first-degree 
relatives to individuals previously hospitalized with SAB would have an increased rate of the infection 
compared with the background population. We further hypothesized that the strongest association 
would be observed among first-degree relatives to an index-case with non-HA SAB. Lastly, we 
hypothesized that the association would be particularly strong among siblings.  
METHODS 
Data sources 
The Danish society is unique due to its universal healthcare system, specifically equal access to 
the health care system free of charge irrespective of social status and insurance coverage. 
Additionally, all the administrative registries are based upon the ten-digit unique personal identification 
number (CPR-number) assigned to all Danish residents at birth or upon immigration, which enables 
cross-linkage of several registries at an individual level and it provides a unique foundation to conduct 
large cohort studies with minimal loss to follow-up.  
In this PhD thesis all data were obtained through cross-linkage of six nationwide registries: The 
Danish Civil Registration System, The National Staphylococcus aureus Database, The National 
Patient Registry, The Medical Birth Registry (Fertility database), The Danish Registry for Medicinal 
Products Statistics (Prescription Registry) and The Population’s Education Registry. 
 
The Danish Civil Registration System 
The Danish Civil Registration System tracks daily changes in vital status (date of birth, date of 
death) and demographics (age, sex, immigration/emigration). The registry was established in 1968 
and no information is deleted from the registry (97). 
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The National Staphylococcus aureus Bacteremia Database 
The National Staphylococcus aureus Bacteremia Repository and Database was established in 
1957 and contains S. aureus positive isolates and clinical information for >90% of all S. aureus 
positive blood cultures in Denmark (98). From all regional hospital departments of Clinical 
Microbiology, one S. aureus isolate from each bacteremia episode is sent to Statens Serum Institut, 
which hosts as the repository and curates the database and furthermore serves as the national 
reference laboratory. Prior to 1992 the isolates were registered according to sample numbers, thus it 
is not possible to combine these numbers with information from other registries. Since 2007 genetic 
information on bacterial isolates (CC-classes and S. aureus protein A [spa] type) have been 
determined and registered. Way of acquisition (hospital acquired versus non-hospital acquired) has 
also been recorded in this registry.  
 
The National Patient Registry 
The National Patient Registry was established in 1978 and comprises data on all hospital 
admissions and invasive interventions, and from 1995 and onwards, the registry also contains 
information on visits in the outpatient care setting. Date of admission, date of discharge, diagnoses 
and procedure codes are recorded in the registry. The exact date of intervention for procedures or 
surgery is included, Until 1994, diagnosis codes were registered according to the 8th version of the 
International Classification of Diseases (ICD-8), and by the 10th version (ICD-10) from 1994 and 
onwards. Reporting is mandatory, and there is a high level of interest in reporting correctly to the 
registry, since the reimbursements to the hospitals are based on the codes registered at time of 
discharge (99,100). The registry has been shown to be accurate (100). 
 
The Danish Registry for Medicinal Products Statistics (Prescription Registry)  
Information on all prescriptions dispensed in Denmark (including date of distribution) has been 
registered since 1995 in the Prescription Registry. Data are registered in accordance with the 
Anatomical Therapeutic Chemical classifications system (ATC) (101).  Validation studies have proved 
the registry to be highly accurate (102). 
 
The Medical Birth Registry (Fertility Database) 
The Medical Birth Registry contains clinical data on all women giving birth (live and stillbirth) in 
Denmark. All pregnant women, irrespective of employment and socioeconomic status, are 
encouraged to participate in an antenatal governmentally financed program with several routine 
appointments at the doctor and midwife. Throughout pregnancy, information is collected in a uniform 
pregnancy chart and selected data from the pregnancy chart is reported to the registry at time of birth 
through a standardized software program including the personal identification number of the child. It is 
further possible to identify siblings and the registered father in the registry. The registry was 
established in 1973 and has been computerized since 1995 (103).  
 
The Population’s Education Registry 
The Population’s Education Registry contains information on the highest completed level of 
education for all individuals in Denmark. The Danish education institutions provide annual information 
regarding enrollment, fulfilled levels of education and exams. In 2008 the registry contained 
information on 96.4% of the Danes aged 15–69 years, and for 85–90% of immigrants (104).   
 
Study design 
For all three papers an observational register-based cohort design was chosen, albeit with 
different methodologies to accommodate specific requirements related to the particular aim of each 
study.  
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Study populations and outcomes 
In all papers the study population was consecutively included during the following periods: 1996–
2011 (Paper I), 2000–2015 (Paper II) and 1992-2012 (Paper III). Individuals emigrating or acquiring 
SAB prior to study inclusion were excluded. All individuals were followed until outcome of interest 
(primarily microbiologically verified SAB), emigration, death, or end-of-study-period, whichever came 
first. 
 
Paper I 
In the first paper of this thesis we assessed the association between socioeconomic status (SES) 
and acquisition of SAB in individuals ≥30 years of age identified 1996–2012. Besides the overall 
exclusion criteria, we further excluded individuals without educational information and all first-
generation immigrants. The study population was stratified into three age-categories (≥30–50, >50–70 
and >70) and information on highest attained educational level (in five categories) at study entry was 
achieved from the Population’s Education Registry. We categorized the educational level as 
described elsewhere (105) and used the highest level of education as our reference: 1) basic school 
(primary, lower secondary); 2) upper secondary (general secondary, technical secondary; “high-
school”); 3) vocational (e.g. electrician or chef); 4) short or medium length higher education (Academy 
Profession Degree, Professional Bachelor’s Degree, University Bachelor’s Degree; 2–4 years 
following upper secondary); 5) Master’s Degree or Ph.D. Further, we examined whether the level of 
SES influenced the risk of subsequent endocarditis (secondary outcome) in patients with SAB. 
Information on endocarditis was achieved from the National Patient Registry (ICD-10 codes I33 and 
I38) and defined as a diagnosis of endocarditis within three months from SAB.  These codes have 
recently been validated with a positive predictive value of 82% (106) and up till 90% when patients 
were hospitalized for over 2 weeks (107). 
 
Paper II 
In the second paper we investigated pre-defined risk factors for SAB in a large pediatric population 
(5–18 years) during 2000–2015 with the child’s 18-year birthday as an additional end of follow-up 
criterium. Cross-linkage of the Civil Registration System, the Medical Birth Registry, the Population’s 
Education Registry, the Danish Staphylococcus aureus Database and the National Patient’s registry 
provided us with information on premature birth, acquisition of SAB, comorbidity burden, surgical 
procedures, and parental socioeconomic status. Children aged 18 years prior to January 1, 2000 or 
immigrating to Denmark following their 18-year birthday were not included in the study population. 
The predefined exposures of interest were: Congenital heart disease, chromosome anomalies, 
cancers, asthma, cystic fibrosis, rheumatic diseases, inflammatory bowel disease, atopic dermatitis, 
diabetes, burn injury, psychiatric disease with a frequent occurrence of self-mutilating behavior, 
pacemaker implantation, prosthetic heart valve or an implanted orthopedic device, undergoing 
transplantation, overall surgery and treatment with dialysis or plasmapheresis (Appendix IV). Among 
children with SAB we further wished to identify presumably healthy children, and defined presumably 
healthy children as children without registered comorbidities, who had no contact with the health care 
system and no claimed prescriptions in the three months prior to SAB and had not undergone 
invasive interventions in the 30 days prior to the bacteremia. 
 
Paper III 
In the third paper, we investigated whether SAB clustered in families with a first-degree relative, 
who had been hospitalized with SAB using the overall rate of SAB in the general population as our 
reference. Cross-linkage of the Danish Medical Birth Registry and the Civil Registration System was 
used to identify and obtain information on all families in Denmark (parents, children, siblings) and 
through the National SAB Database, data of family members previously hospitalized with a first 
episode of SAB was achieved. We excluded children without information on their parents, individuals 
who emigrated prior to study inclusion, stillbirths and adoptees. Families where a parent acquired the 
bacteremia prior to a child was included in the overall analyses, but not in the sub-analyses.  
An overview of the study populations in the three papers and a methodological summary can be 
found in Figure 2 and Table 1. 
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Figure 2: Study population flowchart 
Definitions of covariates 
The definition and codes used for all covariates were defined the same way in all papers and are 
summarized in Appendix IV.  
 
Statistical methods 
In all papers categorical variables were presented as frequencies with percentages, whereas non-
parametric continuous variables were summarized as median with interquartile range (IQR). The 
median follow-up was calculated as the median time between date of inclusion and first occurrence of 
SAB (outcome), emigration, and end of study period or death. Crude incidence rates were presented 
as number of events per 100.000 person-years. 
 
Relative rate analyses 
Survival analysis is fundamental to epidemiological studies examining differences in time to the 
occurrence of a specific event. Since not all individuals in a study population will experience the event 
of interest during the study’s follow-up, their time is censored (right censoring). A crucial assumption 
is that the process giving rise to right censoring is independent of the pathway to event of interest.  
In register-based epidemiological studies both Poisson regression and Cox proportional hazards 
regression (Cox regression) are widely used survival models to study associations between exposure 
variables and time to event of interest. Both models calculate rates of event in exposed and un-
exposed individuals, and the ratio between rates is a measure of the relative risk.  
Poisson and Cox regression models share assumptions on linearity of continuous variables, lack 
of effect modification (no interactions) and that the ratio of rates is constant over time. However, in 
Poisson regression the rate ratio is assumed to be constant within each defined time period, thus to 
evaluate whether the Poisson regression is valid it is essential to test that the results do not change 
with more narrow time intervals. In Cox regression the hazard rate is calculated for each day since the 
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beginning of follow-up. The main assumption in Cox analysis is the proportional hazard assumption, 
that the ratios of hazard for conditions of interest are constant over time.  
The main advantage of Poisson regression analyses is that it is possible and technically simple 
with reasonable computer power to have multiple time-scales and time-dependent covariates in the 
same model. Since our study cohorts were fairly large and the outcome of interest rare, we chose to 
use Poisson regression in all papers. To do so we used the Lexis diagram principle (108) to split the 
observation time in time-bands according to calendar-year and age. Figure 3 displays an example of 
the Lexis principle, where each line represents the contributing risk time of an individual. In this 
example four persons are 30 years old at some point in 2006, and due to different length of the lines, 
they add different risk time to the grey rectangle.  
 
 
Figure 3: The Lexis diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Because of the time-dependent approach, we further split the time of follow-up into time-bands 
according to status of the exposure variables. This enabled each individual to contribute with person-
time at risk in the exposed group and in the unexposed group. We further allowed individuals with 
specific exposure status to switch groups during the study period, e.g. patients requiring treatment 
with dialysis contributed with risk-time for 90 days following the procedure (exposed to dialysis), and if 
no other dialysis treatment occurred, these individuals again contributed with risk time in the group of 
patients without dialysis (unexposed to dialysis). 
In the Poisson regression models a rate of event was calculated for each specific combination of 
calendar year, age and exposure status for all individuals who contributed with person-time to that 
specific combination. 
We reported all estimates with 95% confidence intervals (95% CI) and considered a two-sided p-
value below 0.05 as statistical significant. All data management and statistical analyses were 
conducted in SAS version 9.4 (SAS Institute Inc., Gary, NC, USA). R version 3.4 and Prism 7.0 were 
used for graphics.   
 
Paper I 
In this paper we presented baseline characteristics at time of study inclusion and baseline 
characteristic were compared across socioeconomic levels. Individuals with the highest SES 
constituted the reference group for the primary and secondary analyses (SAB and subsequent 
endocarditis in SAB patient, respectively) and had age and calendar years as underlying time-scales, 
both in one-year time-bands. To ensure that a lack of an association between SES and risk of 
Figure 3: The Lexis diagram visualizes how a given follow-up period is split up 
according to age and calendar year (2005–2008) and how different individuals 
(the 4 lines) contribute with different risk time.  
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subsequent endocarditis in patients with SAB was not due to a fatal outcome among SAB patients 
with low SES (survival bias), we explored the cumulative incidence of SAB with death as competing 
risk. 
 
Paper II 
The majority of children included in Paper II were 5 years old at study inclusion and were healthy, 
thus we found it more relevant to look at characteristics for children acquiring SAB at the time of 
event. The associations between a number of predefined risk factors and SAB were examined in 
separate models using children without the exposure of interest as the reference group and by 
splitting the follow-up period into five-year time-bands since 5- year birthday and one-year age-bands.  
To explore if the rate of SAB was constant over time following exposure, we conducted sensitivity 
analyses examining the incidence rate ratios of SAB according to time elapsed since exposure. For 
most exposures we explored rates during and after 5 years of exposure occurrence, but in 
accordance with previous studies, we limited elapsed time to 90 days following dialysis, and 30 days 
following surgery.  
 
Paper III 
In Paper III we used a different approach with the rate of SAB in the entire Danish population (the 
background population) serving as our reference. We found it appropriate to describe the exposed 
study population according to family status (baseline table). Given the novel design of Paper III, the 
statistical method warrants a more detailed description. Again we chose a population-based 
observational cohort design, but the rates of SAB in the study cohort were compared with rates in the 
general Danish population. The first member in a family to acquire SAB was defined as the index-
case, and first-degree relatives to index-cases comprised our study cohort (exposed individuals). 
Thus, the ‘comparison group’ for the group of exposed was the entire Danish population represented 
by population incidence rates. The resulting standardized incidence rate (SIR) calculations were 
based on individual data on the first-degree relatives and the resulting model was, in principle, a 
standard technique much used in, e.g. cancer incidence studies (26). However, in cancer studies, 
population rates are typically obtained from national cancer registries, whereas we were able to 
calculate ‘our own’ population rates by having access to individual person level data covering the 
entire population of Denmark. Exposed individuals were only compared with individuals within the 
same age- and calendar year time band, thus we accounted for the underlying age differences 
between the background population and the exposed families. Five-year time-bands for both age and 
calendar year were used.  
To accommodate for the risk of a potential familial clustering being due to simple transmission 
between first-degree relatives, we analyzed the genetic pattern of S. aureus for every infected family 
member (index-cases and exposed cases) by determining the spa type.  If the majority of index-cases 
and exposed cases were infected with the same S. aureus spa type it would favor transmission over a 
possible genetic susceptibility to the microorganism. Further, shared environmental factors could also 
explain a familial disposition to SAB, thus we additionally assessed the incidence rate ratio of the 
disease among spouses. All registered partnerships in the entire Danish population were identified 
through the Civil Registration System and updated annually, thus not only married couple but all 
cohabiting couples were included in the variable “spouses”. The risk time began the day one of the 
individuals in a partnership acquired SAB. A high IRR of SAB among spouses would suggest a 
significant influence of shared environmental factors on a familial clustering of SAB.  
 
Ethical aspects 
Danish Data Protection Agency (reference number 2007-58-015/GEH-2014-018 I-Suite 
number_02736) and the Danish Health and Medicines Authority (reference number 2007-54-0295) all 
approved the studies included in the current thesis. A specific approval was achieved from the 
National Research Department at Statens Serum Institut regarding Paper III to obtain information on 
the spa type S. aureus isolates.  
In Denmark, conduction of retrospective registry-based studies does not require ethical approval. All 
data used in the current thesis was held by Statistics Denmark, which additionally had the 
administrative rights to the data.  
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Table 1: Methodological summary 
  
 Paper I Paper II Paper III 
Aims To examine the association 
between socioeconomic 
status and 1) SAB and 2) 
subsequent IE 
To examine the 
association between 
predefined exposures and 
SAB in children 
To examine the associations 
between a family history of 
SAB and risk of SAB  
Study design Registry-based nationwide 
cohort study 
Register-based nationwide 
cohort study 
Register-based nationwide 
cohort study 
Study 
population 
The Danish general 
population ≥30 years 
between 1996–2012 with 
information on education  
All Danish children from 
their fifth birthday between 
2000–2015 
All Danes with information on 
familiar relations between 
1992 and 2012 
Stratification Age-categories: 
o 30–50 years 
o >50–70 years 
o >70 years 
Age-categories: 
o ≤11 years 
o >11 years 
Stratified in  
hospital acquired/non-hospital 
acquired SAB 
Exposure Socioeconomic status Congenital heart disease, 
chromosome anomalies, 
cancers, asthma, 
rheumatic diseases, atopic 
dermatitis, transplantation, 
overall surgery, dialysis or 
plasmapheresis 
Having a first-degree relative 
previously admitted to a 
hospital with SAB 
Exclusion 
criteria 
Prior diagnosis of SAB, first 
generation immigrants, or 
emigration prior to study 
inclusion 
Prior SAB diagnosis, 
emigration prior to study 
inclusion, immigration as 
an adult (≥18 years of 
age) 
For primary analysis: 
Emigration prior to study 
inclusion 
For analyses on family 
status: Children acquiring 
SAB prior to a parent  
Outcomes Primary:  Acquisition of 
microbiologically verified SAB 
Secondary: Infective 
endocarditis (IE) in patients 
with SAB 
Acquisition of 
microbiologically verified 
SAB 
Acquisition of microbiologically 
verified SAB 
Start of risk time January 1, 1996 or date of 
30-year birthday 
The date of 5-year 
birthday, or immigration 
Day of index-case SAB 
Follow-up Primary: Until SAB, 
emigration, December 31, 
2011 or death 
Secondary: Until a diagnosis 
of IE, 90 days after SAB 
diagnosis, emigration, 
December 31, 2011 or death 
Primary: Until 18 year 
birthday, SAB, emigration, 
December 31, 2015 or 
death 
Secondary: Until time 
since exposure had 
elapsed 30 days, 90 days 
or 5 years or 18-year 
birthday, SAB, emigration, 
December 31, 2015 or 
death 
Until SAB, emigration, 
December 31, 2012 or death 
Covariates Age, sex, calendar year, 
hypertension, peripheral 
vascular disease, 
cerebrovascular disease, 
hearth failure, acute 
myocardial infarction, 
valvular heart disease, 
diabetes, cancer, mild/severe 
liver disease, acute/chronic 
renal failure, chronic 
obstructive pulmonary 
disease, atopic dermatitis, 
psoriasis, rheumatic 
disorders, HIV, dialysis 
treatment, prosthetic devices 
and surgical procedures  
Age, sex, calendar year Age, sex, calendar year, 
socioeconomic status, 
comorbidity diabetes, cancer, 
chronic dialysis treatment, any 
surgical procedure, and 
presence of a prosthetic 
device (pacemaker or 
prosthetic heart valve, knee, 
or hip)  
Statistical 
analyses 
Multiple Poisson regression 
analyses, Lexis models and 
Aalen-Johansen estimator for 
cumulative incidence with 
death as competing risk 
Multiple Poisson 
regression analyses and 
Lexis models. 
Multiple Poisson regression 
analyses and Lexis models  
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RESULTS 
This section provides the main results for the three papers in the thesis. Due to the law on 
anonymization from Statistics Denmark, we were not allowed to report results with less than three 
affected individuals, thus these results are reported as <3. Each paper is enclosed in the Appendix 
(Appendices I–III). The figure numbers are related to the numerical order in the thesis and not in the 
published papers. 
 
Paper I 
 
“The associations between socioeconomic status and risk of Staphylococcus aureus 
bacteremia and subsequent endocarditis – a Danish nationwide cohort study” 
 
We included 3,394,936 individuals (50.7% male) and followed them from 1996 to 2012 for a 
median of 15.9 years (IQR = [10.7;16.0]). We observed individuals with low socioeconomic status 
(SES) to be older with a higher comorbidity burden than the other SES groups. During the study 
period we identified 13,181 persons with a first hospitalization for SAB (62.9% male). Overall, we 
observed low SES to be associated with a nearly 2-fold increased risk of SAB compared with the 
highest SES group and adjusted for age, calendar year and sex, Figure 4.  
When stratified by age-categories (p for interaction between age and SES <0.0001), the lowest 
absolute risk of SAB was observed among the youngest group aged 30–50 years (overall 
IR=1.1/100,000 person-years) and the highest absolute risk among the eldest (IR=7.7/100,000 
person-years for individuals >70 years). In contrast, the highest relative risk of SAB was observed in 
the youngest group, and the association was attenuated with advancing age, Figure 5. In all analyses 
stratified by age, no association was observed between having a short/medium length higher 
education and SAB compared with having the highest educational level (Master’s Degree/Ph.D.). The 
inverse association between decreasing SES and increasing risk of SAB persisted when adjusting for 
medical conditions, devices and invasive procedures, albeit the association was attenuated (Figure 5 
in the paper). 
In the post hoc analysis of subsequent endocarditis risk, 776 (5.9% of 13,181 patients) patients 
acquired endocarditis following SAB (IR of 13.1/100,000 person-years). For the majority of patients 
(73%, n=569), endocarditis was diagnosed within the first week after hospitalization with SAB, albeit 
no association between the level of SES and risk of subsequent endocarditis was observed, Figure 6.  
The lack of an association between educational level and subsequent endocarditis in SAB patients 
was not explained by a higher mortality rate among individuals with low SES, since taking competing 
risk of death into account did not change our findings (Figure 6 in the paper). 
 
Figure 4: Incidence rate ratios of SAB according to socioeconomic status 
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Figure 5:  Incidence rate ratios of SAB according to socioeconomic status and 
stratified by age-groups 
 
 
Figure 6: Incidence rate ratios of subsequent endocarditis in SAB patients 
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Paper II  
 
“Staphylococcus aureus Bacteremia in Children Aged 5-18 Years – Risk Factors in 
the New Millennium” 
 
From 2000–2015 we followed 1,109,169 children (5–18 years of age) and observed 307 children 
with a first episode of SAB corresponding to an incidence rate of 3.7/100,000 person-years. The 
incidence of SAB was highest in boys, Figure 7, and 2.6% of the children with SAB died within a year.  
Overall, the absolute rates were low except in children with cancer, in transplanted children and in 
children undergoing dialysis or plasmapheresis, Figure 8. The association between comorbidity and 
rate of SAB did not differ by sex (all p-values for interaction>0.10), however we observed a significant 
interaction between age, and cancer, atopic dermatitis, asthma and surgery, and analyses were 
therefore stratified by age. 
We observed several conditions to be associated with an increased rate of SAB, but due to few 
events (<5), we did not perform relative rates analyses for inflammatory bowel disease, diabetes, 
cystic fibrosis, burn injury, psychiatric disease, children with a prosthetic heart valve, pacemaker or 
orthopedic device.  
Adjusting for age, sex and calendar year exposed the highest relative rates in children receiving 
dialysis or plasmapheresis, in children undergoing organ transplantation and in children with cancer, 
Figure 8. Having a congenital heart disease, chromosome anomalies or a rheumatic disease was 
associated with an up to 7-fold increased rate of SAB. In children with atopic dermatitis the highest 
IRRs were observed in older children (≥11 years, Figure 8), and in analyses accounting for time since 
exposure, the highest IRRs was observed in children ≥11 years within the first 5 years from diagnosis, 
Figure 9B and 9C. The highest estimates in children suffering from cancer, asthma and in children 
undergoing surgery were observed in younger children (<11 years of age, Figure 8), and within the 
first 5 years of cancer or asthma diagnoses and within the first 30 days post-surgery, Figure 9B and 
9C.  
Examining rates according to time since exposure revealed a significant decline in IRRs of SAB for 
congenital heart disease, rheumatic diseases and transplantation when time since exposure elapsed 
more than 5 years, Figure 9A. Conversely, in children with chromosome anomalies, the rate of the 
infection was increased 1.5-fold following 5 years from diagnosis. In children undergoing dialysis or 
plasmapheresis, all events occurred within the first 90 days after procedure, Figure 9A. In sub-
analyses neither prematurity nor parental socioeconomic status predisposed to an increased rate of 
SAB in the children.  
Among children with SAB 37.1% (N=114) were presumably healthy prior to admission (Table 2) 
and of these, boys comprised 62.3%. We observed no differences in age at SAB acquisition was 
observed between boys and girls (age of boys=10.8 [IQR:7.3-14.9], age of girls=10.1 [IQR:8.7-11.5], 
p=0.7427). Overall, in 2.9% (N=9) of the infected children, soft tissue infection was detected at the 
time of SAB, however was present in 6.1% (N=7) of presumably healthy children. None of the children 
with a first episode of SAB had a co-infected sibling at the time of hospitalization (Table 2). Bone and 
joint infection during admission with SAB was observed in 26.4% of SAB children overall and in 
37.7% (N=43) of presumably healthy children. In total, seven (2.3%) children were readmitted with 
SAB within the first year following primary bacteremia of whom three children had cancer.  
The majority of children with SAB had parents with long educations (47% had a university 
education; missing values N=3).  
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Figure 7: Overall Incidence Rate (IR) of SAB in Danish children aged 5–18 years and 
stratified by sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Incidence rate ratios (IRRs) of SAB according to exposures of interest 
 
IRRs of S aureus bacteremia according to exposure of interest in 1 109 169 Danish children aged 5-18 years between 
2000 and 2015. All exposure variables were analyzed in separate models and adjusted for age, sex, and calendar year with 
the reference for each variable being children without the specific condition. N/A, not applicable (too few or no events).   
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Figure 9: Incidence rate ratios of SAB according to time since the date of exposure 
 
  
IRRs of S aureus bacteremia in Danish children aged 5-18 years between 2000 and 2015 for specific 
exposures of interest according to time since date of exposure. All exposures were analyzed in 
separate models and adjusted for age, sex, and calendar year with the reference for each variable 
being children without the medical conditions. Because of significant interaction between the exposure 
and age (P < .05), separate subgroup analyses were performed in children <11 and 11 years 
of age for cancer, atopic dermatitis, asthma, and surgery. N/A, not applicable (too few or no events). 
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Table 2: Characteristics of children hospitalized with a first episode of SAB 
 
CHARACTERISTICS OF CHILDREN ACQUIRING SAB IN THE AGE OF 5–18 YEARS 
N  307 
Boys (%) 197 (64.2) 
Ethnicity (%)  
Ethnic Danes  333 (87.6) 
Immigrants 9 (2.4) 
Descendants 38 (10) 
Not registered 4 (1.0) 
Median age at diagnosis (IQR) 10.6 (8.1-13.4) 
The most frequent CC-classes since 2007 (%)  
CC45 53 (17.3) 
CC30 47 (15.3) 
CC15 20 (6.5) 
CC1 19 (6.2) 
Methicillin resistant S. aureus (MRSA) 8 (2.6) 
Healthcare contact 90 days prior to SAB (%) 104 (33.9) 
Soft tissue infection at SAB diagnosis1 9 (2.9) 
Complicated SAB2 81 (26.4) 
Readmission within 1 year from primary SAB (%) 7 (2.3) 
Co-infected sibling at the time of SAB – 
Medical conditions (%)  
Congenital heart disease 17 (5.5) 
Chromosome abnormalities 5 (1.6) 
Cancer 44 (14.3) 
Atopic dermatitis 20 (6.5) 
Asthma 28 (9.1) 
Influenza at admission – 
Cystic fibrosis <3 (<1.0) 
Rheumatic disease 13 (4.2) 
Diabetes <3 (<1.0) 
Inflammatory bowel disease3 3 (1.0) 
Psychiatric disease4 3 (1.0) 
Burn injury5 – 
Devices and invasive procedures (%)  
Pacemaker <3 (<1.0) 
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Prosthetic heart valve 3 (1.0) 
Orthopedic devices6 4 (1.3) 
Transplantation (solid organ or bone marrow) 8 (2.6) 
Undergoing surgery 30 days prior to SAB (%) 53 (17.3) 
Dialysis or plasmapheresis  10 (3.3) 
Presumably healthy children7 (%) 114 (37.1) 
SAB= S. aureus bacteremia 
1Soft tissue infection comprised cellulitis, impetigo, superficial abscesses and bursitis. 2Complicated SAB was defined as 
SAB with secondary bone or joint foci. 3Inflammatory bowel disease: Mb. Crohn and Colitis ulcerosa. 4Psychiatric: 
personality disorder, anorexia, bulimia, anxiety, affective mental disorder, schizophrenia or psychosis (not drug-induced) 
5Burn injury: Burn injury requiring contact to the emergency department or hospitalization. 6Orthopedic devices: Device 
material due to treatment of fractures and hip implants. 7Previously healthy children were defined as children without 
comorbidities, without contact to the health care system and no claimed prescriptions three months prior to SAB, and had 
not undergone invasive interventions in the 30 days prior to the bacteremia 
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Paper III  
 
“Familial Clustering of Staphylococcus aureus Bacteremia in First-degree Relatives: 
A Danish Nationwide Cohort Study” 
 
We included 34,774 first-degree relatives (exposed) to 18,626 individuals previously hospitalized 
with SAB (index-cases) between 1992 and 2011.  
In general the study cohort was young and the comorbidity burden at baseline was fairly low. Only 
few of the first-degree relatives received dialysis treatment or had implanted devices, Table 3.  
During the study period 65 first-degree relatives were diagnosed with a first episode of SAB 
(infected–exposed cohort) corresponding to an incidence rate of 20.8/100,000 person years.  
Overall, having a first-degree relative with a history of SAB was associated with a more than 2-fold 
increased standardized incidence ratio (SIR) of SAB compared with the Danish background 
population, Figure 10. The rate was particularly high when the index-case had been admitted to 
hospital with a non-HA bacteremia and when the index-case was a sibling, Figure 10.  
Although limited by few events, analyses stratified by sex of the index-case revealed the highest 
SIRs of SAB in exposed individuals whose index-case was a brother with a non-HA infection, Figure 
11. Further, we observed significantly higher estimates among exposed to a male index-case with 
non-HA infection (brother or father), whereas no significant differences by sex were observed in 
parents or siblings (p for interaction = 0.85 and 0.92, respectively).  
Adjustment for diabetes, cancer, dialysis treatment, implanted foreign material (prosthetic heart 
valve, pacemaker, or hip or knee prosthesis), and any surgery prior to study inclusion or during follow-
up attenuated the results, albeit the associations remained significant with the highest SIR of disease 
still observed in siblings and in individuals whose first-degree relative had been hospitalized with non-
HA bacteremia.  
Since none in the infected–exposed cohort had inflammatory bowel disease or rheumatoid arthritis 
at baseline or during follow-up, adjustment for these conditions was not feasible. Within the families 
the causative S. aureus strain had identical CC-type in only 6 index-case patients and their 
corresponding first-degree relative (6 from the infected–exposed group), equivalent to 18.5% of the 65 
families with an infected–exposed member. Of these, four index-cases and their related cases (67%) 
were twins less than 1 year of age. We found CC45, CC30, and CC15 to be the most frequent clonal 
lineages represented in the 65 families, which corresponded to the most prevalent clonal lineages in 
the Danish Staphylococcal Bacteremia Database (CC45, 20%; CC30, 15%; and CC15, 11%).  
In 57% of the exposed individuals, more than three years had elapsed from the date of the index-
SAB to the SAB event of the exposed person. Introduction of a 1-year quarantine period after the 
index event did not alter our primary findings, albeit estimates were slightly attenuated. We observed 
no increased risk in spouses to individuals with SAB (SIR, 0.82 [CI, 0.54 to 1.25]).  
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Table 3: Baseline characteristics of first-degree relatives to individuals previously 
admitted to hospital with SAB  
 
Characteristic Siblings Offspring 
  Maternal Paternal 
Persons, n 6727 10 414 17 633 
Male 3553 (52.8) 5489 (52.6) 9415 (53.9) 
Age    
<30 y 3439 (51.1) 3386 (32.5) 5852 (33.2) 
30–40 y 1503 (22.3) 3114 (29.9) 5872 (33.3) 
41–50 y 1387 (20.6) 3021 (29.0) 4890 (27.8) 
51–60 y 377 (5.6) 879 (8.4) 1008 (5.7) 
>60 y 21 (0.30) 14 (0.10) 11 (0.1) 
Inflammatory bowel disease 36 (0.5) 69 (0.7) 129 (0.7) 
Rheumatoid arthritis 14 (0.2) 38 (0.4) 50 (0.3) 
Cancer 36 (0.5) 70 (0.7) 126 (0.7) 
Diabetes 99 (1.5) 161 (1.5) 279 (1.6) 
Renal disease    
Acute renal failure 16 (0.2) 15 (0.1) 24 (0.1) 
Chronic renal failure 13 (0.2) 23 (0.2) 20 (0.1) 
Glomerular disease 15 (0.2) 24 (0.2) 22 (0.1) 
Dialysis† 3 (0.04) <3 (0.03) 5 (0.03) 
Health care system contact 
≤30 days prior to inclusion 
   
Emergency department <3 (0.04) <3 (0.03) 8 (0.05) 
Outpatient visits 13 (0.2) 26 (0.2) 29 (0.2) 
Hospitalized for 12 h 0 (0) 0 (0) 3 (0.02) 
Hospitalized for ≥24 h 27 (0.4) 13 (0.1) 25 (0.1) 
Devices‡ <3 (<0.04) 5 (0.05) <3 (<0.02) 
Surgery§ 35 (0.5) 32 (0.3) 76 (0.4) 
 
*Values are numbers (percentages) unless otherwise indicated. Percentages may not sum to 100 due to 
rounding. † Dialysis treatment regardless of indication within 6 months prior to study inclusion. ‡ Implantation of a 
pacemaker (regardless of type), prosthetic heart valve, or hip or knee prosthesis within 1 year prior to study 
inclusion. § Any type of surgery within 1 month prior to inclusion. 
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Figure 10: Standardized incidence ratios of SAB for exposed overall, by family status 
of the index-case and by way of bacteremic acquisition of the index-case 
 
 
The model is adjusted for sex, age, and calendar year. NA = not applicable; SIR =standardized incidence ratio. 
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Figure 11: Standardized incidence ratios for SAB in first-degree relatives stratified by 
sex, method of bacteremic acquisition, and family status of the index-case patient 
 
 
The model is adjusted for sex, age, and calendar year. NA = not applicable; SIR = standardized incidence ratio.  
 
 
 
 
  
  
0.2 0.5 1.0 2.0 5.0 10.0
2.07 (1.04−4.15)
1.96 (0.98−3.92)
2.01 (1.23−3.29)
1.24 (0.62−2.48)
2.62 (1.63−4.21)
1.93 (1.30−2.86)
3.71 (0.93−14.84)
3.11 (1.01−9.64)
3.33 (1.38−7.99)
3.92 (1.47−10.43)
6.98 (4.05−12.02)
5.89 (3.66−9.48)
8
8
16
8
17
25
2
4
6
5
13
18
5,247
5,167
10,414
9,126
8,507
17,633
859
1,522
2,381
1,502
2,844
4,346
(ref)
SIR (95% CI) N N events
N/AN/A
Hospital-acquired
Non−hospital acquired
Brother
Background population
Groups
Hospital-acquired
Non−hospital acquired
Sister
Hospital-acquired
Non−hospital acquired
Father
Hospital-acquired
Non−hospital acquired
Mother
15.0
SIR
SAB - host factors influencing the human infection risk 
	 32	
DISCUSSION 
SAB is a rare disease in otherwise healthy individuals as confirmed by the low absolute risks in all 
three papers constituting this thesis. As a result hereof, even a few extra events in one exposure 
group would lead to a high relative risk, e.g. a 2-fold increased risk could be from 1/10 to 2/10, and 
1/1,000,000 to 2/1,000,000. Importantly, the main focus in this thesis was not the absolute risks of 
SAB, but rather an understanding of factors influencing the acquisition of the disease, e.g., the 
association with low SES particularly in young adults, that a significant proportion of children acquiring 
SAB was previously healthy, and that genetics may have a role since this rare disease appeared to 
cluster in families.  
 
Paper I 
Main findings 
In an adult population above 30 years of age we observed the level of SES to be inversely 
associated with SAB particularly in adults between ≥30–50 years of age. SES was not associated with 
subsequent infective endocarditis (IE) in patients with the bacteremia and the lack of an association 
was not explained by a higher mortality rate in SAB patients of lower SES compared with SAB 
patients of high SES. 
 
Comparison to other studies in the field 
Various measures have been used to reflect SES across studies (e.g. income, education, 
crowding, low income areas), nevertheless the literature indicate that low SES increases the general 
risk of infectious diseases (19,27,28,90,109–112). In New Zealand and Australia severe infectious 
diseases including SAB are a major cause of hospitalizations with strong inequality in SES and 
ethnicity (19,26,90). In both countries the rate of SAB is markedly higher among individuals of lower 
SES and with the Pacific Islanders, Maoris and the indigenous people in Australia being the most 
vulnerable compared with European and non-indigenous people, respectively. An index score 
constructed from various variables e.g. educational level, occupation type, employment status, 
income housing status and single parenthood status was used to define SES in these studies.  
In a Danish case-control study exploring the association between SES and community-acquired 
bacteremia in working-age people SES was measured according to both income and educational 
level. The researchers stated that in contrast to income, educational level may be a better marker of 
SES when people are young, whereas income may reflect SES better later in life. For both markers a 
low level was associated with an increased risk of bacteremia and the substantially higher burden of 
alcohol and drug abuse among individuals with low SES explained close to 50% of the differences in 
bacteremia rate across SES levels (27). Studies have found that an increased susceptibility to 
infections in people of lower SES could be explained by poorer hygienic practices, household 
crowding, more smoking, poorer nutrition and less use of vaccines (90). In countries without a 
universal healthcare system inequalities in access to hospitals and professional healthcare treatment 
are probably explained by differences in the ability to finance sufficient health insurance and could 
also explain a longer patient delay in individuals from the most deprived social class. However, in 
Denmark the access to the healthcare system and medical treatment is equal and free of charge 
irrespective of SES.  
The literature further suggests variations in comorbidity burden as a mediator of the significant 
disparities in the rate of infectious diseases, including SAB, across SES levels. Several chronic 
diseases have been observed to be more prevalent among individuals of low SES e.g. diabetes 
(48,50), liver disease (56), cancer (113), human immunodeficiency virus infection (59,114) and 
conditions related to substance abuse, which are all associated with increased risk of SAB. However, 
adjustment for several chronic diseases only attenuated our results.  
Although SAB is a prominent cause of IE worldwide, and complications to SAB frequently occur in 
individuals of low social status (27,115), we are not familiar with other studies examining the 
association between SES and the risk of subsequent infective endocarditis (IE) in patients with SAB.  
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Methodological considerations 
To examine the association between SES and risks of SAB and subsequent IE we followed all 
Danish citizens ≥30 years of age. The lower age limitation was chosen to make sure that the majority 
of the population had finished their education. In un-published analyses we tried to set the age-limit at 
25 and 35, which did not change the results significantly.    
The association between SES and acquisition of SAB differed by age (p for interaction <0.0001), 
thus we stratified the population into three age groups: 1) 30–50 years of age, 2) >50–70 years of age 
and 3) >70 years of age. In Denmark the official age of retirement is 65 years, however it is becoming 
increasingly common for the elderly to keep working after the age of 65 years, thus the higher 
threshold was chosen to ensure that patients in this age group were in fact retired. Changing the age-
categories in a supplemental analysis revealed that the increased estimates were still driven by the 
increased risk in the youngest subjects, which supports our age-categorization.  
In our study, we used educational level as a marker for SES, which is unlikely to change markedly 
after early adulthood and more important it is a strong predictor of an individual’s future occupation 
and thereby also future income (116). In a Danish case-control study the researchers chose to only 
include individuals in the working-age arguing that educational level and income is a less reliable 
measure of SES in the elderly (27,116). An ideal way of defining socioeconomic status in either 
extremes of life does not exist. Despite this limitation, we were interested in examining if the level of 
SES was associated with the risk of acquiring SAB throughout adulthood. Since educational level is 
known to reflect income later in life (116), we chose to define SES in accordance with highest attained 
educational level at study inclusion. If SES had been defined by income a number of individuals would 
have been categorized as having a lower SES: 1) Students who are given subsistence throughout 
their studies, i.e. particularly individuals with the longest education would be misclassified, 2) newly 
educated individuals who receive a lower salary after end of their studies (e.g. doctors) and 3) retired 
individuals who receive pension. However, our results did not change when income was used as 
socioeconomic marker in a supplemental analysis.  
Lastly, a number of studies have observed SAB to be more frequent among different ethnic groups 
(e.g. Indigenous people, Pacific-Islanders, Maoris, African-American) and further suggest that the 
higher rate of S. aureus infections and SAB among people of lower SES could be mediated by 
ethnicity (19,28,90,111,113,117). We chose not to stratify our analyses by ethnicity since 1) ethnic 
Danes constituted approximately 90% of the Danish population during the study period, thus the 
variety in ethnicity is minor compared to other countries in the world (e.g. the United States, Australia 
and New Zealand), 2) we chose to exclude immigrants since the Population’s Education Registry 
does not include educational information on educations fulfilled in the home country of immigrants. 3) 
Differences in susceptibility to S. aureus among diverse ethnic populations was not only explained by 
a higher comorbidity burden and more deprived household living among individuals with low SES but 
also on access inequality to the healthcare system. Denmark has a unique universal healthcare 
system with equal and free access for all citizens irrespective of SES, thus we believe that differences 
in ethnicity regarding SAB risk would only influence our results a little.   
 
Novelty 
This paper is the first nationwide cohort-study exploring the association between not only the level 
of socioeconomic status and acquisition of SAB but also whether SES is associated with the risk of 
subsequent endocarditis in SAB patients. Since the associations were strongest in the youngest (30–
50 years), these results suggest that the physician should pay extra attention to younger individuals of 
low socioeconomic status, particularly when they present with diffuse symptoms. 
 
Paper II 
Main findings 
Paper II explored potential risk factors for SAB in a nationwide pedatric poplution between 5 and 
18 years of age. SAB was uncommon in children above five years, Factors prone to increase the risk 
of SAB in adults (dialysis, plasmapheresis, receiving organ transplantation and having cancer) were 
associated with the highest relative rates in children aged 5–18 years. More than a third of the 
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infected children were presumably healthy, emphasizing the need for awareness of the disease also 
in children without identified risk factors. Premature birth and parental socioeconomic status did not 
increase the disease rate as observed in studies including younger children. 
 
Comparison to other studies in the field 
Overall our main findings were in line with published studies of selected and smaller children 
populations and studies of adults. Dialysis, plasmapheresis, surgery and organ transplantation were 
all strongly associated with SAB in our child cohort, as observed in other pediatric studies 
(39,66,118). One study including 68 children receiving dialysis found that 33% of the pathogen 
cultured were coagulase-positive and of these 72% were S. aureus (39). Another study identified 38 
S. aureus infections among 698 transplanted children of which 15.3% were bacteremia. The majority 
of S. aureus infections (90.2%) occurred more than six months after the transplantation, and heart 
transplantation was associated with the highest risk of bacteremia (66).     
Further, we observed congenital heart disease, rheumatic diseases and chromosome anomalies 
to be associated with acquisition of SAB. Congenital heart disease is often diagnosed within the first 
year of life in particularly if the disease confers hemodynamic problems. Moreover, in these children 
surgery is often necessary, and a combination of invasive procedures, long hospitalizations in children 
with an age-related immature immune system markedly increases the infection risk (119). In our child 
cohort, congenital heart disease increased the incidence rate of the bacteremia more than 3-fold, 
which was probably explained by late diagnosis in some of the children and surgery later in life due to 
a less severe heart disease.   
Having a rheumatic disease was associated with more than a 6-fold increased rate of SAB in our 
child cohort within the first 5 years after diagnosis. A study from Finland observed juvenile idiopathic 
arthritis to be associated with a 3-fold increased risk of bacteremia, whereof S. aureus was a 
frequently observed pathogen (44). Additionally, a study from the United States found an increased 
rate of infections requiring hospitalization especially among children treated with glucocorticoids, 
which has also been confirmed in adults (121). Whether it is the inflammatory aspect of the disorder 
or the immunosuppressive medication used to stagnate the disease, which confers the increased risk 
of SAB is not fully elucidated.  
Moreover, our study might be the first population based study to reveal an increased rate of SAB 
in children with Trisomi 21 (Down’s Syndrome). Although, studies on SAB in children with 
chromosome anomalies are rare, a study from the United States including 26 patients with Down’s 
Syndrome observed a high occurrence of SAB in these children (122). Additionally, children with 
Down’s Syndrome suffer from a compromised immune system, often have an increased rate of S. 
aureus skin infections and a high comorbidity burden (122,123), thus have an increased risk of SAB. 
Further, a study from Oxford revealed a 19-fold increased rate of leukemia and an over 2-fold 
increased rate of type 1 diabetes in children with Down’s Syndrome, medical conditions known to 
increase the risk of SAB compared with children without the disease (124).  
In line with other studies conducted in children and adults (32,34,118) cancer was strongly 
associated with SAB. The doubled incidence rate of SAB in children with cancer <11 years of age, 
and the marked decline in the relative risk after five years from diagnosis could be explained by more 
than 80% of Danish children diagnosed with cancer between the age of 0–15 years being alive and 
cancer-free five years from diagnosis. Further, the majority of these children are not in the need for 
intravenous accesses prone to increase the infection risk.  
Further, atopic dermatitis and asthma were associated with acquisition of SAB. In children with 
atopic dermatitis the rates of SAB were highest among children above 11 years of age and within the 
first 5 years after diagnosis. The median time of atopic dermatitis persistence is 3 years from 
diagnosis. Most children remit from their atopic dermatitis during childhood, but children with severe 
disease or late onset of the disease have an increased risk of persistence in adultness (125). This is 
in accordance with our observation that in children with atopic dermatitis the rates of SAB were 
highest among children above 11 years of age and within the first 5 years after diagnosis. In contrast, 
asthma was only associated with increased acquisition of SAB in children younger than 11 years of 
age, which could be because childhood asthma remits in approximately 50% of children before the 
age of 18 years (126).   
Co-infection with influenza at the time of hospitalization with SAB is well-known in children and 
complications with necrotizing pneumonia due to S. aureus confers a major cause of death in children 
with influenza (127,128). It would have been of great interest to examine the association between 
influenza and acquisition of SAB, however none of the children acquiring SAB in our study had a 
diagnosis code of influenza at the time of hospitalization, thus impeding further analyses.  
SAB - host factors influencing the human infection risk 
	 35	
The association between parental socioeconomic status, prematurity and acquisition of SAB was 
among the variables, which is far from elucidated. A few studies (two Danish and one Swedish study) 
have shown that low parental educational level, low parental income and living in low medium income 
areas are associated with an increased risk of hospitalization in children less than 5 years of age 
(29,30,129). Importantly, children younger than 5 years old have an age-related impaired immune 
system, which could have influenced the results from these studies. In contrast we observed no 
association between parental socioeconomic status and SAB in children between 5 and 18 years of 
age, which may be explained by our inclusion of an older child population with a more robust immune 
system. Moreover, the lack of an association could be because risk factors increasing the risk of SAB 
in adults with low SES (e.g. diabetes with complications, manifest cardiovascular disease and 
intravenous drug abuse) are simply not present in children aged 5–18 years of age.  
The older child cohort likely explains why premature birth was not associated with acquisition of 
SAB in our population as observed in other studies (120,130), indicating that children born 
prematurely and surviving the first five years without acquiring SAB have a risk of SAB comparable to 
that of children born at term.  
Although the majority of children hospitalized with SAB suffer from comorbidities, our study 
confirmed that presumably healthy children constitute a significant proportion of children with SAB 
(25,74,89,118,131,132). In an American study examining 151 children with SAB, 47.4% (N=27) were 
considered healthy prior to SAB (50% of the children were younger than 1 year of age when acquiring 
the bacteremia). A British study examined 2,364 consecutive episodes of bloodstream infections in a 
children’s hospital and observed 281 (11.9%) children to be previously healthy prior to the infection 
(74). Investigators from New Zealand observed significant part of SAB children <16 years to be 
previously healthy (89). In an Australian study 59% of previously healthy children presented with bone 
or joint infection prior to SAB (119). In our study we observed bone and joint infections to be more 
frequent in presumably healthy children compared with comorbid SAB children. These findings also 
underscore that the proportion of previously healthy children in SAB cohorts is highly dependent on 
patient selection and definition of “healthy”.  
.  
Methodological considerations  
Studies of risk factors for SAB in the pediatric population are sparse and the current literature is 
mainly of descriptive character and focuses on infants. Due to the vulnerability in the first years of life, 
we specifically chose to focus on children aged 5–18 years, thus children who were not challenged by 
an age-related immature immune system and thinner skin-barrier (133,134). Further, we specifically 
chose to name previously healthy children as “presumably healthy children”, since it was out of the 
scope of this paper to reveal whether these children were in fact healthy or whether the onset of SAB 
was a proxy for an underlying disease to be discovered.   
Since our population was limited to children aged 5 to 18 years, we were limited by fewer events 
compared with other studies in the field, since the incidence of SAB are high among infants, and thus 
we only adjusted for the most important confounders in the statistical models.  
We chose to include children born from January 1, 1995 and later even though information 
regarding microbiologically verified SAB was available before this date. This decision was made since 
information on prescribed and subsequently claimed medication and outpatient care was not available 
prior to 1995. The latter is specifically important since children in Denmark are often referred from the 
general practitioner to outpatient care settings instead of being hospitalized, thus hypothetically we 
would underestimate exposed children by including years where information on outpatient care was 
not available.     
The definition of dialysis and plasmapheresis conferred further considerations. Dialysis and 
plasmapheresis are rare in children, but are strongly associated with increased risk of SAB and are 
two similar procedures conducted through a rather large intravenous catheter. We therefore found it 
reasonable to combine these procedures in one variable.  
Lastly, the main model used in this study anticipated constant rate ratios over time, but assuming 
that the rate of SAB would be constant regardless of time since exposure would be incorrect. 
Therefore, in a supplemental analysis we examined the rate of SAB according to time since exposure. 
Due to a median follow-up of 7.8 years (IQR: 3.6-11.9) a 5-year period was considered appropriate for 
permanent exposures (e.g. congenital heart disease, diabetes, rheumatic disease). A 90-day period 
was chosen for children receiving dialysis or plasmapheresis in accordance with the current literature. 
A 30-day period was chosen for children undergoing surgical interventions due to a general 
consensus that infections or bleeding within 30 days post-operatively is likely to be a consequence of 
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the surgical procedure. However, since we did not differentiate between surgical procedures with or 
without implantation of a foreign body, 90 days may have been more appropriate since studies have 
revealed an increased risk of infection within the first 90 days after surgery when a foreign body was 
implanted. Nonetheless, we believe that this is a minor limitation, since implantation of a foreign body 
in children is rare.  
 
Novelty 
To the best of our knowledge Paper II is one of the largest studies in the field of SAB in children 
and unique in the number of pre-defined exposures explored in a nationwide setting with universal 
access to the health care system. Further, we wanted to examine potential risk factors for SAB in a 
pediatric population, which was not influenced by an underlying age-related vulnerability to infectious 
diseases due to an impaired immune system. Thus, in contrast to other studies, we specifically chose 
to include children above the age of 5 years since children between the age of 5 and 18 should be 
able of eradicating an invasive S. aureus in contrast to younger children. Also, we are not aware of 
other studies examining parental SES as a potential risk factor in this case. Besides increasing the 
awareness of the bacteremia in children with comorbidities, these results also encourage the 
physician to consider this diagnosis even though a child is presumably healthy (no chronic diseases, 
no contact with the healthcare system 3 months prior to SAB and no medication 3 months prior to 
hospitalization with SAB).  
Additionally the results pave the way for future pediatric studies to explore sex differences in risk 
profile especially in the early teens, and to investigate if SAB is a marker of an underlying disease in 
previously healthy children. If not it would be of great interest to conduct a study in these children	 to 
reveal potential genetic differences among healthy children acquiring SAB compared with an age- and 
sex-matched child cohort without SAB. Importantly, this study should include information on all factors 
that could potentially increase the risk of SAB such as visits to the dentist and comorbidities treated 
solely at the general practitioner or by the help of doctors from private clinics, which was not possible 
in Paper II. 
 
 
Paper III 
Main findings 
The main findings were that having a first-degree relative with a first episode of microbiologically 
verified SAB increased the risk of acquiring the disease compared with the risk in the general 
population. The observed increase in relative risk of SAB was low compared with risk associated with 
other risk factors for this bacteremia (e.g. cancer, HIV, catheter placement) but age-related 
comorbidities were considered to only comprise a minor confounder since we studied a cohort of 
relatively young and healthy individuals.  
 
Comparison to other studies in the field 
Familial aggregation has been observed for other infectious diseases. In a Swedish cross-
sectional study on monozygotic and dizygotic twins the authors observed a genetic influence on the 
susceptibility to H. Pylori. Both twins reared apart and reared together were examined, and shared 
environmental factors were observed to also influence the susceptibility (135). Further, in a 
population-based study from the United Kingdom the authors observed an up till 30-fold increased 
risk of meningococcal disease among siblings compared with the rate of infection in the general 
population (136). When more than one year had elapsed between the index-case event and the case 
event, the relative risk declined to an 8-fold increased risk, nevertheless still suggesting that a genetic 
component could play a role in the susceptibility to Neisseria meningitidis. However, the study was 
based on questionnaire data, which might have been subject to recall bias. Conversely, a Danish 
study following 43,134	 relatives of individuals with invasive pneumococcal disease revealed an 
increased infection risk among closely related persons (parents, children, siblings and half-siblings), 
but only when the relative acquired the infection within the first year of the index case. The increased 
risk was probably caused by shared environmental factors and no increased risk was observed in 
SAB - host factors influencing the human infection risk 
	 37	
third generation family members (grandparents), or when the relatives did not share the same 
household with the case (137). In contrast, the main findings of our study remained close to unaltered 
when only events of SAB occurring one year after the index date was explored and when only 
individuals aged 20 years and older were considered at risk. Further, in most cases, more than three 
years elapsed from index-case event to case event and >80% of the infected cases were infected 
with a S. aureus strain genetically different from the index-case making direct transmission unlikely to 
drive these results. Given that no increased rate among spouses was observed, our results did not 
appear to be driven by shared environmental factors.  
If genetic host factors influence the susceptibility to S. aureus, it is reasonable to expect that the 
risk would be attenuated as familiarity becomes more distant. However, information in The Danish 
Fertility Registry about parents to individuals born in Denmark was not complete until 1954 and 
onwards, which precludes an analysis about risk in grandchildren. The same argument precludes 
analyzes of the risk of SAB in cousins, since the cousins have to be identified through their parents, 
thus the cousins possible to identify would be too young for analyses to be reasonable, particularly 
since SAB most often appears in the elderly.   
Host genetics would also be assumed to be mostly relevant to community-acquired SAB, since 
several non-genetic factors may play a role for acquisition of HA SAB (e.g. indwelling catheters, 
medical devices and surgery). Interestingly, stratifying the way of acquisition in the index-case into HA 
and non-HA SAB revealed higher relative rates of bacteremia in cases to non-HA index-cases, and 
the first-degree relatives to non-HA index-cases were more likely to acquire non-HA SAB themselves. 
In contrast, in index-cases hospitalized with HA SAB, the distribution of non-HA and HA SAB were 
equally distributed among the cases. All together, these findings support the hypothesis that genetic 
host factors play a role in the susceptibility to S. aureus.  
Several studies have examined the influence of host genetics on the susceptibility to S. aureus, 
where the ability to transfer genetic susceptibility to the microorganism between different mice species 
is considered a strong indicator that genetic host factors play an important role in the sensitivity to S. 
aureus (77–79). Moreover, a number of studies have examined genetic host factors in humans 
related to increased infection risk and suggest mutations in several candidate genes such as two 
genes on chromosome 11 (80), STAT3 (leading to Job’s syndrome) (94) and alterations causing 
IRAK-4 (interleukin-1 receptor-associated kinase 4) deficiency (92). Additionally, mannose-binding 
lectin deficiency, present in 5–10% of all individuals, impairs the innate immune system, increases the 
risk of infections with S. aureus and influences the outcome of patients with infective endocarditis 
(82,138). No common variants were observed to increase the risk of SAB in a recent genome-wide 
association study, however this research did not address low-frequency or rare variants that may be 
associated with increased susceptibility in humans, and the study was further hampered by a small 
study size (96). In contrast another recent study observed variations in the gene GLS2 to be 
associated with complicated SAB.  
In contrast in a study using whole exome sequencing (WES) in patients with complicated SAB 
(endocarditis/bone or joint infections), variants in GLS2 was observed to be associated with 
complicated SAB. GLS2 regulates the production of glutamine, thus indirectly the activation of T-cell 
production which is essential for combatting SAB, which makes GLS2 an interesting candidate gene 
(139).  
 
Methodological considerations  
In this paper the study population consisted of first-degree relatives (cases) to individuals 
previously admitted to a hospital with a first episode of SAB (index-cases). We chose to exclude 
adopted children, even though these children would appear ideal for elucidating environmental and 
genetic influence on SAB occurrence. An increased risk in adoptees would suggest that 
environmental factors or unmeasured confounders rather than genetics would be responsible for a 
familial clustering of the infection. There are however important limitations to such an analysis, which 
would make the results difficult to interpret. First, adopted children represents a tiny part of the Danish 
population, and information on adoptees was only included from 1980 and onwards. Secondly, there 
is an insufficient registration of the adoptive parents, thus for 38.6% of the adoptees, information on 
the adoptive parents’ identification numbers were missing which prohibited us from obtaining 
information on SAB. However, we identified 33,626 children, who were registered as adopted in 
Denmark during our study period of whom 20,525 adopted children had parental information (n 
excluded due to missing data on parents=12,996). Of these children, 188 adoptees had a first-degree 
relative with SAB, but none of the adoptees (children/siblings) acquired the disease, thus precluding 
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any additional analyses.  
Another limitation to the study was that approximately 10% of registered fathers are not the 
biological fathers (140). As a final minor limitation, the father to children conceived through sperm 
donation would not appear in the registry. Since single mothers often prefer to use the same sperm 
donor, these children would be detected as half-siblings in the data management process, although 
they have the same mother and father. 
One could argue that a matched case-control study would be simpler for the reader to understand, 
however we believe that our approach had at least two advantages compared to having an ‘internal, 
unexposed control group’ obtained, e.g., by matching 10 unexposed subjects by age, sex, and period 
to each exposed first-degree relative. First, we used all the data from the country on incidence of SAB 
(and not only data from the ~34.000 exposed and 10*34.000 matched unexposed), which is 
advantageous for this rare condition. Second, a more subtle advantage is that by comparing the 
exposed group to the entire population instead of comparing to an “unexposed” group, we avoid a 
potential (albeit small) misclassification of exposure by not knowing about exposure before 1992. In a 
matched case-control study we would also know for certain that the ~34.000 exposed are truly 
exposed but among the matched unexposed there might be few with a first-degree relative diagnosed 
prior to 1992.  
 
Novelty 
We are not familiar with other studies exploring a familial clustering of SAB and the method is the 
first of its kind, thus Paper III is unique in several aspects. Knowledge on familial clustering can lead 
the way for future genetic research to clarify whether and to which extend a genetic component is 
present in the risk profile of SAB and explore the possibility for identifying high-risk groups, and 
potentially prophylactic actions. Further, the method can be used in many scientific fields to serve as 
a pilot study prior to large, expensive genetic studies.  
 
Strengths and limitations  
Randomized controlled trials are the “Gold standard” in research. However, due to ethical, 
practical and financial circumstances randomized controlled trials are not always feasible. The studies 
comprising this thesis were observational and based on historical data obtained from numerous 
Danish administrative registries, thus none of the variables included in our models were self-reported 
or achieved from questionnaires, thus recall bias was not an issue.  
Although the epidemiological approach has limitations, it additionally has several advantages. The 
studies were conducted in a nationwide setting with a universal healthcare system, which minimized 
selection bias particularly for Paper I and Paper III. Further, the risk of missing data or incorrect 
reporting was limited since most of the nationwide registries function as governmental administrative 
registries, and it would therefore have financial consequences if reimbursement were missed. 
Moreover, the continuous reporting to the registries over decades provided large study cohorts with a 
minimal loss to follow-up, which is crucial when exploring rare events.  
Importantly, SAB was the primary outcome in all papers, information on which was achieved from 
the National Surveillance Database, thus despite the use of registries, our outcome was 
microbiologically verified. Further, our primary analyses in all three papers were adjusted for age, sex 
and calendar year, which are three very robust variables. Particularly important for Paper II, we 
achieved information on comorbidities and invasive procedures from the National Patient Registry 
(100). Although a number of validation studies have been published, the majority of validation studies 
are conducted in the adult population, thus it is not examined if the diagnosis codes registered at 
discharge in the patient files for children are compliant with the codes in the registry. The majority of 
validation studies have studied the positive predictive values of the diagnoses defined as the 
compliance between the discharge diagnosis in the registry, and the discharge diagnosis in the 
medical record. However, only a few validation studies have studied the true positive predictive 
values, thus whether the patients actually have the diseases, nor examined the sensitivity of the 
diagnosis codes, thus whether patients with the disease achieve the correct diagnosis code 
(99,106,107,141). The discharge diagnoses are assigned by the treating physicians and the results of 
all register-based studies must therefore always be interpreted in light of the circumstances under 
which the clinicians contribute to the registries, e.g. the death certificates constituting the National 
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Causes of Death Registry are often the result of doctors speculating on the causes of death, 
sometimes without having ever met the patient. The independent variable (educational level, SES) in 
Paper I was achieved from a valid register where above 96% of education for all individuals between 
15 and 69 are recorded (104). Likewise, information on first-degree relatives was achieved by 
combining The Civil Registration System and the Fertility Register, and although an estimated 10% of 
Danish children have another biological father than the one registered in the registries the 
independent variables in Paper III must be accounted robust.  
 
The PhD thesis has limitations, which merit comments. The observational design of the studies 
made examination and interpretation regarding associations possible whereas further prospective 
studies are warranted to confirm our results and explore causality. The factors identified as 
associated with the risk of SAB may thus not be risk factors, but rather markers of unmeasured 
confounders. Observational studies will almost always be influenced by residual confounding, thus 
influenced by inadequately or unmeasured factors. In all papers we were not able to investigate if 
there was regional differences in SAB incidence, obtain information on conditions handled by the 
general practitioner or immunosuppressive medications not requiring a prescription (e.g. 
chemotherapy administered at the hospital or particularly expensive drugs e.g. rimactan dispensed 
from the hospital), identify focus of the infection, or achieve information on nasal carriage of S. aureus 
or drug abuse, which could potentially have influenced our results. Specifically, in Paper I 
microbiological information about patients with endocarditis was not available to us in any registries, 
thus all endocarditis events may not have been caused by S. aureus. However, the possible 
overestimation most likely only constituted a minor limitation since we made a restrictive definition by 
only including endocarditis within three months following a SAB event. Consequently, this might have 
underestimated the number of endocarditis events in patients with SAB, which additionally could 
explain the lower frequency observed in our population compared with other studies in the field.  In 
Paper III it would have been desirable to adjust for geographical region in the analyses since our 
results could have been confounded by geographical region if cases of the disease clustered by 
geographical region, e.g. countryside versus urban city. This would acquire detailed geo-mapping, 
which was outside the scope of this paper. Also it would only be relevant for non-HA SAB. 
Additionally, the contribution with isolates to the database could have differed by region, which we 
believe constitutes a minor problem since the reporting by the departments of microbiology was 90-
95% during the study period.  
In Paper II and Paper III, we were restricted by the rarity of SAB, which limited inclusion of 
covariates in the adjusted models.  
Confounding by indication was not an essential problem for the main findings in Paper I and Paper 
III, however for some exposures of interest (e.g.: atopic dermatitis, cancer, rheumatic disease) in 
Paper II, it was not possible to quantify whether the increased rate of SAB was due to the 
pathophysiology of the disease or the treatment medication leading to the classic “ chicken and the 
egg” causality dilemma.  
 
Clinical implications 
The interplay between host factors and acquisition of SAB is complex and far from fully understood. 
SAB patients often have a poor prognosis due their often multi-comorbid status prior to SAB and 
significant delays in the diagnosis (patient’s delay and doctor’s delay) increasing the likelihood of 
complications. The studies comprising this PhD thesis were only hypothesis-generating, but several 
potential risk factors for acquisition of SAB in nationwide and unselected populations were identified. 
An increased awareness of the disease even in young and healthy individuals is important. Although 
SAB is rare in young adults, our results suggest that young individuals hospitalized with SAB more 
frequently are of lower SES, and increased awareness should be paid to this patient category. 
Further, it was reassuring that once diagnosed with SAB, SES was not associated with risk of 
infective endocarditis. Furthermore, our results emphasizes the importance of an increased 
awareness of the disease, especially in children and young adults, where above one third must be 
considered to be at an a priori low risk. The findings in Paper III suggest that genetics may play a role, 
which should be further investigated in clinical trials and then maybe a family history of SAB will be a 
part of the identification of high-risk patient groups and part of the medical history of patients 
suspected to have bacteremia.  
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CONCLUSION 
	
In this thesis we demonstrated that low socioeconomic status was inversely associated with SAB 
particularly in young adults (30-50 years of age), and of novelty the level of socioeconomic status was 
not associated with subsequent IE in patients with SAB. We further demonstrated that a significant 
number of risk factors, also some known from the adult population, was associated with SAB in 
children above 5 years and that age at time of comorbidity diagnose and time since diagnose 
influenced the risk of SAB for specific diseases. Importantly, above one-third of children acquiring 
SAB were presumably healthy prior to the infection. Finally, we showed that SAB clusters in families 
and having a first-degree relative previously admitted with SAB increases the risk more than six times 
for some family members. The increased risk was not fully explained by shared environmental factors 
or direct contamination among the closely related individuals.   
  
 
 
PERSPECTIVE FOR FUTURE RESEARCH 
	
The papers constituting this thesis were all studies of observational design, thus hypotheses-
generating and therefore preclude conclusions on causality between exposures and SAB acquisition. 
Consequently, further studies are warranted to confirm our findings and to explore the associations in 
more details. It would be relevant to explore the social gradient from Paper I in more details by 
investigating whether specific professions are associated with increased risk of SAB and in addition 
whether housing influencing the risk of acquiring SAB. Also of interest would be to investigate whether 
working-age adults return to work full-time after the admission for SAB or whether these individuals do 
part time jobs or become unemployed, thus receive financial support from the government.   
Further, from Paper II, it would be highly relevant to explore whether presumably healthy children 
were in fact healthy or the occurrence of SAB was a marker of an underlying disease. This should be 
further investigated by examining the cohort of presumably healthy children from the date of hospital 
admission with SAB and 1 year ahead to reveal the proportion of children, in which an underlying 
severe disease (e.g. cancer, diabetes, congenital heart disease) were diagnosed during the 
admission for SAB or shortly after. In children where a first episode of SAB was not a proxy for 
another disease, it would be interesting to conduct genome sequencing to identify potential genetic 
patterns, which result in increased susceptibility to S. aureus in a population, which is not influenced 
by an age-related higher comorbidity burden. In principle, this study could be extended to include all 
presumable healthy SAB-cases between 5 and 30 years of age, since comorbidity burden would 
probably be fairly low in this group.  
Another essential study to be made is to reveal whether genetic risk factors observed in animal 
studies are also present I human. This could be investigated by identifying genetic risk factors in 
patients diagnosed with SAB but without established risk factors (people with high probability of 
genetic risk factors) and compare this group with a group of patients with a high number of risk factors 
but without any incident of SAB (people with low probability of genetic risk factors). 
Our study about familial clustering of SAB has already led to the initiation of genetic research 
within the research group and in collaboration with doctors’ abroad. Additionally, the statistical 
approach used in Paper III has primarily been used in cancer research but is a new and unique 
method to explore whether a well-defined infectious disease clusters in families, which can be 
important alone, and as a pilot study prior to large-scale, expensive genetic studies. Further, this 
model can be applied to other diseases. Finally, the method used in Paper III gives the opportunity to 
assess the hypothesis regarding familial clustering of infectious diseases and at the same time take 
shared environmental factors and risk of transmission into account, and we believe that the specific 
findings for this study will lead to studies of genetic susceptibility to SAB in the future. Future 
advances in the field of genetics might lead to development of new and fast diagnostic tools, new 
treatment modalities, and thereby improved outcome in SAB. 
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Appendix I 
 Appendix I: CODES AND DEFINITIONS OF COVARIATES 
 Codes Definitions 
MEDICAL CONDITION   
Premature birth Gestational week (GA) is a variable 
in the Medical Birth Registry 
Gestational week<37 was 
considered premature 
according to guidelines 
Congenital heart disease DQ20-DQ28  
Congenital chromosome 
anomalies 
DQ90-DQ99 
 
 
Cystic Fibrosis DE84, 273  
Influenza DJ09-DJ11  
Inflammatory bowel disease DK50, DK51, DM07.4, DM07.5 
569.05, 563.19, 563.01 
A diagnosis of Mb. Crohn or 
Colitis Ulcerosa 
Atopic dermatitis DL20, 691  
Chronic heart failure DI110, DI157, DI42, DI43, DI50  
Acute myocardial infarction DI21, DI22 and 410  
Arrhythmias  DI44-DI49 (but not in: DI46)  
Valvular heart disease DI351, DI371, DI361, DI342, DI352, 
DI360, DI370, DI372 
 
Periphery vascular disease DI70, DI74, 443  
Cerebrovascular disease DI60-DI69, 430-438  
Chronic obstructive pulmonary 
disease 
DJ42, DJ44, 490–492  
Diabetes DE10-DE14, 249, ACT=A10 Individuals with a diagnosis of 
diabetes or a prescription of 
glucose lowering medication 
Hypertension DI10-DI15, ACT=C02 Defined as either a diagnosis 
of hypertension followed by a 
subsequent prescription claim 
for an antihypertensive drug 
within 90 days, or as claimed 
prescriptions for two different 
classes of antihypertensive 
drugs. 
 
Acute renal failure DN17, DN19, DR34, 584 A diagnosis code of acute 
renal failure 
Chronic renal failure DN18, DI12, DI13, 585 (but not in: 
DI129, DI132) 
A diagnosis code of chronic 
renal failure 
Other renal diseases DN03, DN04, 582, 583, 596, 588 or 
DI129  
 
Mild liver disease DK70-DK77 (but not in: DK766, 
DK711, 571) 
 
Severe liver disease DK766, DK711, DK704, DB150, 
DB160, DB190, 572, 456 
 
Asthma DJ45, 493  
Chronic obstructive pulmonary 
disease 
DJ42, DJ44, 490-492  
Psoriasis DL40, DM070-DM073, 69609, 
69610, 69619 
ATC: D05AX 
Psoriasis was present if an 
individual had a diagnosis of 
psoriasis or a prescription of 
vitamin D analogue was 
redeemed 
Rheumatic disease Adults: DM05, DM06, DM32-DM34, 
DM353, 7100, 7101, 7104, 7140, 
7141, 7148, 725 
Children:  DI00, DI01, DI018, DI019, 
DM09, DM12, DM13, DM32, DM33, 
DL940, DL941, DM34 (but not in: 
DM341, DP838D, DD690B, DM797) 
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Cancer DC00-DC97, 196, 199 A diagnosis of cancer 
diagnosed within 5 years prior 
to study inclusion 
HIV DB20-DB23  
Psychiatric disease DF2, DF3, DF4, DF50, DF60, DF93, 
DF982, 295, 301 
Psychiatric disease where 
self-injuring behavior is 
frequently observed 
Burn injury T201, T211, T221, T231, T241, 
T251, T291, T202, T212, T222, 
T232, T242, T252, T292, T203, 
T213, T233, T243, T253, T293,  
N940-N949 
A diagnosis of burn injury, 
thus it required contact to the 
emergency department or 
hospitalization 
Bone or joint infections DH050C, DK102C, DK102D, 
DM461-62, DM86, DM00, DM77 
(but not in: DM869A-C) 
 
Soft tissue infections DH050B, DJ383C, DE060A, 
DE236A, DG060A-F, DG061A + B, 
DG079A + B, DH000A, DH050A, 
DH440A, DK130A, DK140A, 
DK209A, DK353A + B, DK052A, 
DJ387G, DJ383D, DM869A-C, 
DH601, DJ340, DJ387, DJ391, 
DL983, DA064-66, DD733, DE321, 
DG062, DJ851, DJ390, DJ369, 
DK047, DK113, DK122, DM600, 
DL010, DL022, DL89, DS910, 
DS912 
 
 
INVASIVE PROCCEDURES, 
DEVICES AND SURGERY  
  
Renal replacement therapy   
Dialysis and plasmapheresis as 
combined variable 
BJFD DZ992 BOQP0 A procedure code of dialysis 
or plasmapheresis and 
considered at risk 90 days 
after. 
Chronic dialysis treatment BJFD (but not in: BJFD0)  
Pacemaker BFCA, BFCB, KFPF, KFPG 
(but not in: BFCA4, BFCB4, BFCA5, 
BFCA88, BFDB8, BFCA9) 
 
Prosthetic heart valves KFMD10, KFMD11, KFMD14, 
KFKD10, KFGE10, KFJF10, 
KFJF30, KFMD20, KFMD30, 
KFKD20, KFGE20, KFMD00, 
KFKD00, KFGE00, KFJF00 
KFJF20, 31269, 31129, 31130, 
30729 
 
Any type 
Orthopedic device DS52, KNJC (but not in: KNJC0), 
KNEJ09, KNEJ19, KNEJ29, 
KNEJ39, KNEJ49, KNEJ69, 
KNEJ79, KNEJ89, KNEJ99, KNFJ2-
KNFJ9, KNFG2-KNFG9, KNFT39, 
KNFT49, KNFB, 
KNFC, 75200-75299 
 
Surgery overall K (but not in: KU, KZ, KX, KY, 
KDHD10, KDJD30, KECB41, 
KEDC32, KEDC34, KEDC35, 
KEEC20, KEEC30, KEGC35, 
KNAH00, KNAH20, KNBH00, 
KNBH10, KNBH20, KNCH00, 
KNCH20, KNDH00, KNDH10, 
KNDH20, KNEJ09, KNFH00, 
KNFH20, KNGH00, KNGH10, 
KNGH20, KNHH00, KNHH10, 
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KNHH20, KTED00, KNAJ0, KNBJ0, 
KNFK0, KNGJ0, KNHJ0, KFQA, 
KFQB, KGDF, KJJC, KJLE, KKAS, 
BOQF). 
322.09, 322.29, 322.50, 356.09, 
472.70, 472.79, 488.40, 488.49, 
574.80, 574.90 
Transplantation KFQA, KFQB, KGDF, KJJC, KJLE, 
KKAS, BOQF, 32250,32229,32219, 
32209 
Solid organ and bone marrow  
OTHER   
Parental Socioeconomic status  Highest attained educational 
level in parents at the date of 
child study inclusion.  
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